Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Qyuns Therapeutics

Request full access

HKEX-listed developer of monoclonal and bispecific antibodies for autoimmune and allergic diseases

Taizhou, ChinaFounded 2015Biotech & Life Sciences

About Qyuns Therapeutics

Qyuns Therapeutics Co., Ltd. is a clinical-stage biopharmaceutical company established in 2015, with its headquarters in Taizhou, China. The company, founded by Mr. Qiu Jiwan who also serves as the Chairman and General Manager, is focused on the research, development, and commercialization of antibody drugs for autoimmune and allergic diseases. Mr. Qiu has expressed confidence in the company's long-term value through a voluntary lock-up of his shares.

The company's business model centers on developing a pipeline of biologic therapies and then commercializing them, often through strategic partnerships with established pharmaceutical companies to maximize market reach and potential. Revenue is generated through these collaborations and from the sale of its approved products. Qyuns Therapeutics successfully listed on the Hong Kong Stock Exchange in March 2024 under the stock code 2509.HK, raising approximately $31.10 million to fund the continued development of its portfolio.

Qyuns has developed a diverse and synergistic product pipeline that covers four major disease areas: dermatology, rheumatology, respiratory, and gastroenterology. A key asset is its rabbit-based antibody discovery platform, which is noted for offering greater diversity and affinity compared to traditional mouse-based technologies. Its pipeline includes multiple candidates at various stages of clinical trials. One of its initial products, SAILEXIN® (a ustekinumab biosimilar), co-developed with Huadong Medicine, is the first of its kind approved in China for treating psoriasis. Other core products in late-stage development include QX002N for ankylosing spondylitis and QX005N for prurigo nodularis, the latter of which has received Breakthrough Therapy Designation. The company actively collaborates with partners like Hansoh Pharma and Joincare to co-develop specific drug candidates, such as QX004N for psoriasis and QX008N for severe asthma and COPD, respectively.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
9
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Mar 2022 $31M $254M TriWise Capital —
SERIES BOther financing Apr 2021 $41M $254M Undisclosed ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Qyuns Therapeutics website traffic

Latest recorded traffic for Qyuns Therapeutics is 2.7K monthly website visits, up 58.8% over the last three months.

Latest monthly visits2.7K 3-month web change+58.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Qyuns Therapeutics in the Taizhou ecosystem

Live from Dealroom

The Qyuns Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Hongtai Aplus
  • TriWise Capital
  • Lucky Source Funds
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Taizhou HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Qyuns Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Qyuns Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.